Ferrari reported strong financial results for Q1 2026, with net revenues reaching €1,848 million, up 3% year over year. Operating profit (EBIT) rose to €548 million, representing a 29.7% margin, while EBITDA totaled €722 million with a 39.1% margin. Net profit came in at €413 million, resulting in diluted earnings per share of €2.33. Industrial free cash flow was particularly
Analysts raise HD targets post-Q4. The expanding Pro ecosystem and FY26 guidance drive recovery hopes, with shares 23.5% undervalued.
Goldman Sachs warns the UK is extremely exposed to jet fuel rationing and summer flight cuts due to the Iran war and zero strategic reserves.
The Federal Reserve hints at a wait and see approach for May. This predictability is narrowing the buyer-seller gap in the global M&A and private credit sectors.
Ryanair will close its Berlin base in October 2026, cutting UK-Germany flights by 50%. The airline blamed high taxes and a 10% fee hike for the move.
The S&P 500 reached an unprecedented 7,230.12 points today. Global investors are buoyed by strong Q1 earnings and cooling inflation data in major economies.
Alphabet rose 5% on cloud gains; Meta fell 10%. Investors worry Meta lacks a cloud business to monetize its massive AI spending compared to hyperscaler peers.
Greg Abel takes the helm as Berkshire Hathaway's CEO at this year's annual meeting, marking the first time Warren Buffett has stepped aside.
Bangladesh is set to sign a deal for 14 Boeing aircraft, reversing a previous plan to buy from Airbus. The shift aims to modernize Biman's fleet and address a $6 billion trade imbalance with the U.S. to protect garment exports.
Qualcomm shares jumped 15% after hours as CEO Cristiano Amon signaled a smartphone market bottom and a major expansion into data center chips. Despite light Q3 guidance, the push into AI inference and custom ASICs fueled investor optimism.
Nvidia's B300 AI servers have hit $1 million in China, nearly double U.S. prices. Tightening U.S. export curbs and a crackdown on black-market smuggling have created a massive scarcity premium for Chinese tech firms.
Italy's economy grew 0.2% in Q1, beating expectations. Despite the beat, the government cut its annual growth outlook to 0.6% due to energy prices and Middle East turmoil.
A poll shows 52% of Swiss voters support capping the population at 10 million. The June 14 initiative seeks to end free movement with the EU to curb rapid growth.
Glencore's copper output surged 19% to 199,600 tons, driven by higher grades in Africa. Its marketing unit is now set to exceed annual earnings targets.
Nvidia shares surged to record highs, reclaiming a $5 trillion valuation as semiconductor demand continues to outpace supply amidst a global AI infrastructure race.
GE HealthCare cut its 2026 forecast due to inflation in chips and freight, sending shares down 9%. Q1 profit missed estimates despite strong revenue growth.
StanChart profit hit $2.45B, up 17% despite a $190M Iran war charge. Growth in wealth and capital markets offset risks, sending HK shares up 4%.
Core capital goods orders jumped 3.3% in March, far exceeding forecasts. Driven by the AI boom, this surge suggests business investment bolstered Q1 growth.
The goods gap rose 5.3% to $87.9B in March as imports outpaced exports. This may drag on Q1 GDP growth, even as vehicle imports and local inventories climb.
Economic data shows Germany is finally rebounding from stagnation. Fiscal support and AI investments are cushioning the impact of global energy price shocks.
The SEC has sharpened its focus on private funds as redemptions top $15 billion. Publicly traded credit vehicles are now trading at deep discounts to their NAV.
Investors are bracing for the Federal Reserve's April 29 meeting. Markets price a 99% probability of a hold at 3.75% as inflation remains stubbornly at 3.3%.
Google joined OpenAI and xAI in a deal to provide AI for classified Pentagon use. The contract bars autonomous weapons without human oversight and mass surveillance.
Novartis leadership warned that the reality of new US drug pricing policies will significantly impact pharmaceutical margins and R&D over the next 18 months.